ArticleMolecular cancer therapeutics2021

Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.

Bin Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.